Simple jQuery Dropdowns
Please use this identifier to cite or link to this item:
Title: Challenges for achieving safe and effective radical cure of Plasmodium vivax: a round table discussion of the APMEN Vivax Working Group
Authors: Kamala Thriemer
Benedikt Ley
Albino Bobogare
Lek Dysoley
Mohammad Shafiul Alam
Ayodhia P. Pasaribu
Jetsumon Sattabongkot
Elodie Jambert
Gonzalo J. Domingo
Robert Commons
Sarah Auburn
Jutta Marfurt
Angela Devine
Mohammad M. Aktaruzzaman
Nayeem Sohel
Rinzin Namgay
Tobgyel Drukpa
Surender Nath Sharma
Elvieda Sarawati
Iriani Samad
Minerva Theodora
Simone Nambanya
Sonesay Ounekham
Rose Nanti Binti Mudin
Garib Da Thakur
Leo Sora Makita
Raffy Deray
Sang Eun Lee
Leonard Boaz
Manjula N. Danansuriya
Santha D. Mudiyanselage
Nipon Chinanonwait
Suravadee Kitchakarn
Johnny Nausien
Esau Naket
Thang Ngo Duc
Ha Do Manh
Young S. Hong
Qin Cheng
Jack S. Richards
Rita Kusriastuti
Ari Satyagraha
Rintis Noviyanti
Xavier C. Ding
Wasif Ali Khan
Ching Swe Phru
Zhu Guoding
Gao Qi
Akira Kaneko
Olivo Miotto
Wang Nguitragool
Wanlapa Roobsoong
Katherine Battle
Rosalind E. Howes
Arantxa Roca-Feltrer
Stephan Duparc
Ipsita Pal Bhowmick
Enny Kenangalem
Jo Anne Bibit
Alyssa Barry
David Sintasath
Rabindra Abeyasinghe
Carol H. Sibley
James McCarthy
Lorenz Von Seidlein
J. Kevin Baird
Ric N. Price
Menzies School of Health Research
National Vector Borne Disease Control Programme
National Center for Parasitology, Entomology and Malaria Control
National Institute of Public Health
International Centre for Diarrheal Diseases and Research
Universitas Sumatera Utara
Mahidol University
Medicines for Malaria Venture (MMV)
Mahidol-Oxford Tropical Medicine Research Unit
Nuffield Department of Clinical Medicine
Ministry of Health and Family Welfare
Ministry of Health in Bhutan
Ministry of Health and Family Welfare
National Malaria Control Program
National Center for Entomology Parasitology and Malaria Control
Kementerian Kesihatan Malaysia
Minister for Health and Population Nepal
National Malaria Control Programme
Department of Health Manila
Korea Centers for Disease Control & Prevention
Ministry of Health Colombo
Thailand Ministry of Public Health
National Malaria Control Programme
National Institute of Malaria, Parasitology, and Entomology (NIMPE)
Access Bio Inc
Australian Army Malaria Institute
Burnet Institute
Ministry of Health, Republic of Indonesia
Indonesian Medical Association
Eijkman Institute of Molecular Biology
Jiangsu Institute of Parasitic Diseases
Karolinska Institutet
Osaka City University
Wellcome Trust Centre for Human Genetics
Wellcome Trust Sanger Institute
Malaria Consortium
Indian Council of Medical Research
Yayasan Pengembangan Kesehatan dan Masyarakat Papua Timika
Walter and Eliza Hall Institute of Medical Research
University of Melbourne
United States Agency for International Development
Organisation Mondiale de la Santé
University of Washington, Seattle
QIMR Berghofer Medical Research Institute
Eijkman-Oxford Clinical Research Unit
Keywords: Immunology and Microbiology
Issue Date: 5-Apr-2017
Citation: Malaria Journal. Vol.16, No.1 (2017)
Abstract: © 2017 The Author(s). The delivery of safe and effective radical cure for Plasmodium vivax is one of the greatest challenges for achieving malaria elimination from the Asia-Pacific by 2030. During the annual meeting of the Asia Pacific Malaria Elimination Network Vivax Working Group in October 2016, a round table discussion was held to discuss the programmatic issues hindering the widespread use of primaquine (PQ) radical cure. Participants included 73 representatives from 16 partner countries and 33 institutional partners and other research institutes. In this meeting report, the key discussion points are presented and grouped into five themes: (i) current barriers for glucose-6-phosphate deficiency (G6PD) testing prior to PQ radical cure, (ii) necessary properties of G6PD tests for wide scale deployment, (iii) the promotion of G6PD testing, (iv) improving adherence to PQ regimens and (v) the challenges for future tafenoquine (TQ) roll out. Robust point of care (PoC) G6PD tests are needed, which are suitable and cost-effective for clinical settings with limited infrastructure. An affordable and competitive test price is needed, accompanied by sustainable funding for the product with appropriate training of healthcare staff, and robust quality control and assurance processes. In the absence of quantitative PoC G6PD tests, G6PD status can be gauged with qualitative diagnostics, however none of the available tests is currently sensitive enough to guide TQ treatment. TQ introduction will require overcoming additional challenges including the management of severely and intermediately G6PD deficient individuals. Robust strategies are needed to ensure that effective treatment practices can be deployed widely, and these should ensure that the caveats are outweighed by the benefits of radical cure for both the patients and the community. Widespread access to quality controlled G6PD testing will be critical.
ISSN: 14752875
Appears in Collections:Scopus 2016-2017

Files in This Item:
There are no files associated with this item.

Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.